<DOC>
	<DOCNO>NCT03095326</DOCNO>
	<brief_summary>Splenectomized thalassemia major subject provide PCV pneumococcal vaccine ( Prevenar 13® ) start trial , follow randomly assign 2 group ( zinc placebo group ) . After 8 week , subject receive PPV pneumococcal vaccine ( Pneumovax® ) . Zinc syrup provide zinc group dose 1.5 mg/kg/day ( maximum 50 mg/day ) . Pneumococcal IgG examination conduct start trial 12 week .</brief_summary>
	<brief_title>Pneumococcal Vaccination Splenectomised Thalassemia Major Patients Indonesia</brief_title>
	<detailed_description>This study single blind randomised-control trial . Splenectomized thalassemia major patient sample provide PCV pneumococcal vaccine ( Prevenar 13® ) start trial , follow randomly assign 2 group ( zinc placebo group ) . After 8 week , subject receive PPV pneumococcal vaccine ( Pneumovax® ) . Zinc syrup provide zinc group dose 1.5 mg/kg/day ( maximum 50 mg/day ) . Placebo contain sucrose syrup form , taste , consistency color give group . Everyone except primary researcher blind treatment placebo actual zinc syrup . Pneumococcal IgG examination conduct start trial 12 week . Sample size measure use : n1=n2=n= { ( ( Zα+Zβ ) Sd ) /d } ^2 N = number subject Za = degree significance ( 5 % ) , = 5 % Zb = strength study ( 80 % ) . b = 20 % Sd = standard deviation = meaningful difference two group The measured sample size 816 , due limit patient total population sample use instead .</detailed_description>
	<mesh_term>Thalassemia</mesh_term>
	<mesh_term>Pneumococcal Infections</mesh_term>
	<mesh_term>beta-Thalassemia</mesh_term>
	<mesh_term>Vaccines</mesh_term>
	<mesh_term>Zinc</mesh_term>
	<mesh_term>Zinc Sulfate</mesh_term>
	<criteria>Splenectomised thalassemia patient nonsplenectomised thalassemia patient</criteria>
	<gender>All</gender>
	<minimum_age>N/A</minimum_age>
	<maximum_age>N/A</maximum_age>
	<verification_date>March 2017</verification_date>
</DOC>